BNT163

Phase 1Biologic

BioNTech

BNT163 is one of 3 biologic programs targeting Genital Herpes. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Genital HerpesActive, not recruiting

Genital HerpesPhase 1

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Genital Herpes

#DrugCompanyPhaseTrials

Famvir

Novartis

Approved

4 2

Zovirax

BBp Consulting, Inc

Approved

5 3

BNT163

BioNTech

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Genital Herpes

NCT05432583

Clinical

Trials by Indication[1]

Genital Herpes1 trial

A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

Active, not recruiting· BioNTech logo

BioNTech·Phase 1·NCT05432583·318 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BNT163. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BNT163 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BNT163. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: BioNTech

BNT163

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Genital Herpes1 trial

References

Drug Info

Quick Facts

Related News